Opening of CRANN’s Advanced Microscopy Laboratory

When: TUESDAY 27th APRIL 2010

Where: AML
Unit 27-29
Trinity Enterprise Centre
Grand Canal Quay
Dublin 2, Ireland

The CRANN Advanced Microscopy Laboratory (AML) houses a critical mass of high end electron and ion beam
microscopes, for sample imaging, material characterisation and nanofabrication, in a custom built facility. This world
class operation is managed by a dedicated team of highly trained scientists and engineers with a wide range of scientific
and industrial experience. By engaging with this facility, commercial users can achieve a competitive advantage by
supplementing their own in-house capability with this first class microscopy facility.

MORNING SESSION: INDUSTRY WORKSHOP

9:30–10:15 Tours of CRANN Research Facility available to

industry representatives. RSVP as below

10:30 Arrival of Industry Guests

10:45–11:30 Introduction

Overview of CRANN – Dr. Diarmuid O’Brien,

Executive Director.

Carl Zeiss Presentation – TBD.

AML Facility Presentation – Mr. Fergal Keating,

Microscopy Facility Manager.

11:30–12:30 Industry Case Studies: Increased

competitiveness through partnership

Intel – Mr. Leonard Hobbs,

Research Programmes Manager.

Cellix – Dr. Vivienne Williams, CEO.

Hewlett Packard – Dr. Lorraine Byrne,

Engineering Program Manager.

SolarPrint – Dr. Mazhar Bari, CEO.

Boston Scientific – Dr. Fergal Horgan,

R&D Engineer.

Eblana – Dr. Brian Kelly,

Director of Manufacturing.

Millipore – Dr. Thomas Fitzgerald,

Research Scientist.

12:30–1:00 Concluding Remarks with Questions & Answers

Industry Engagement funding models –

Dr. Diarmuid O’Brien

1:00 Lunch & Networking

1:30–2:00 Tour of the AML Facilities

AFTERNOON SESSION: FORMAL OPENING OF THE AML

2:15 Arrival of guests for formal opening

2:30–3:00 Opening of AML Facilities

Opening remarks by:

The Provost – Dr. John Hegarty

Minister of Enterprise, Trade and Innovation –

Mr. Batt O’Keeffe, TD

Director General of SFI – Prof. Frank Gannon

CEO of the HEA – Mr. Tom Boland

R&D Director, Boston Scientific – Mr. Rob Eyers

CRANN Director – Prof. John Boland

3:00–3:30 Reception

Tours of the AML Facilities

3:30 Tour of CRANN Research Facility

Please RSVP your availability for the morning and/or afternoon sessions and morning tours of CRANN to Lia Beveridge, email: lia.beveridge@tcd.ie, tel: 01 896 3027 by the 20th April, 2010

The TCD Technology Transfer Office
in association with

The School of Biochemistry and Immunology TCD

presents a seminar by
Professor Andrew Porter

“Commercialising Biotechnology”

Joly Lecture Theatre, Hamilton Building (map), TCD
4PM, Friday April 23rd, 2010

RSVP: gordon elliott at tcd.ie

Andrew Porter is Professor of Biotechnology and Deputy Director of the Institute of Medical Sciences at the University of Aberdeen. He was founder and CSO of University spin-out Haptogen Ltd. which was acquired by Wyeth in October 2007.
Haptogen developed a proprietary human therapeutic antibody platform designed for discovery and optimization of protein therapeutics with improved profiles. The benefits include the potential for more convenient routes of administration as well as cell and organ penetration, addressing diseases that are not treatable with first generation protein therapeutics.
Prior to Haptogen, Prof. Porter was one of the founding academics and Research Director of Remedios Ltd, Aberdeen. Remedios, a biosensor company, was Scottish biotech of the year in 2000.
In 2005 Prof. Porter was Ernst and Young Plc, Scottish & UK Science and Technology Entrepreneur of the Year and in 2006 be became a Fellow of the Royal Society of Edinburgh.
Since the sale of Haptogen, Prof. Porter has remained active within the biotechnology sector and together with his Haptogen co-founders he has established a venture fund, Grampian Bio-partners, that recently made its first investment in an anti-infectives company based in Scotland.
Prof. Porter was recently appointed to the BioIndustries Association (BIA) Scotland Committee)

InterTradeIreland Venture Capital Conference 2010
How to Raise Equity Capital for Early Stage Companies in a Challenging Environment
Wednesday 26th May, Waterfront Hall, Belfast

Trinity Reserach & Innovation received the emailbelow about the above conference. TEN suggests you contact your own funding agency regarding the details:
We are delighted to announce this year’s Venture Capital Conference, full details of which can be found on www.intertradeireland.com/vcconference2010 .
The ninth InterTradeIreland Venture Capital Conference is a ‘back to basics’ event focusing on raising the early rounds of equity for early-stage companies.
The conference will showcase the current sources of equity capital available, both institutional and through the business angel networks on the island.
The conference brings together investors and entrepreneurs from across the island in an exclusive networking environment. Delegates will have a unique opportunity to meet with investors during networking breaks throughout the day.
In order to attract the most suitable SMEs to the conference InterTradeIreland have made provision for a limited number of places to be made available to client SMEs from development agencies on the island.  I am delighted to offer you the opportunity to nominate a maximum of 4 clients who you feel would benefit from these places, at a cost of £25 per person including VAT.
In order to avail of these places, please email contact and company names along with email addresses and contact phone numbers to intertradeireland@morrowcommunications.com for each person you are putting forward.
Once approved, your client companies will be contacted directly and asked to register online to secure their place at the conference.
As demand is expected to be high for these places, I would ask you to provide the above information as soon as possible, but no later than Friday 16th April 2010.
Kind regards
Gary Stokes
Deputy Manager EquityNetwork
InterTradeIreland